Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter

To release full third quarter 2025 financial results on November 13th; conference call to followTORONTO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today announced preliminary unaudited revenues for the third quarter of 2025. Unless specified otherwise, all amounts in this press release a ...